A Phase 1 interventional study of EB8018 (First-in-class FimH blocker) in Crohn Disease, sponsored by Enterome. Completed at 5 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-02.
Sponsored by Enterome · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 316 studies in Crohn Disease with a site in France — 79 open to participants now, 103 under way, 29 of them phase 3. Crohn Disease · France.
Among the 316 studies in Crohn Disease with a site in France, this one is the 225th largest by enrollment of the 228 interventional ones that give a count, is one of 25 that started in 2018, is one of 5 in phase 1, and was the 160th registered.
1,995 studies on the registry are indexed under Crohn Disease; 477 are open to participants now.
Browse Crohn Disease studies →79 of the 316 studies in Crohn Disease with a site in France are open now. Recruiting first, the newest first:
Central Hospital, Nancy, France · Sites in France
Ages 18+
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives · Sites in France
Ages 18+
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives · Sites in France
Ages 18+
Janssen Research & Development, LLC · Sites in France, United States, Argentina and 27 more countries
Ages 18+
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives · Sites in France
Ages 18–75
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 353 Crohn Disease studies recruiting now, 155 (44%) set no upper age limit and 143 (41%) stop at 75 or younger; 94 take children under 18; 56 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
316 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 64 · Phase 3 86 · Phase 4 16
First in 1990; this study’s year is marked. 25 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 8 is below the median of 67 across 1,262 interventional studies indexed under Crohn Disease.
Median enrollment 147 across the 228 interventional studies, 240 across the 87 observational. Of the 195 that completed or were terminated, 78 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
150 of 316 have an industry lead sponsor. The 10 most frequent:
Enterome is the lead sponsor of 8 studies on the registry; none are open to participants now.
Enterome has 2 studies filed under Crohn Disease — fewer than ten, so there is no comparison to draw.
32 of the studies in Crohn Disease with a site in France that are under way reach primary completion within a year, 8 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04777656Phase 3Assistance Publique - Hôpitaux de ParisUse of Crohn's Disease Exclusion Diet on Top of Standard Therapy Versus Standard Therapy Alone in Unstable Pediatric Crohn's Disease Patients. | 2026-11 |
| NCT05347095Phase 3Janssen-Cilag Ltd.A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease | 2027-03-25 |
| NCT04997733Phase 3Assistance Publique - Hôpitaux de ParisFecal Microbiota Transplantation in Crohn's Disease as Relay After Anti-TNF Withdrawal | 2027-05-22 |
| NCT06408935Phase 3Janssen-Cilag Ltd.Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients | 2027-06-08 |
| NCT06227910Phase 3TakedaA Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease | 2027-06-08 |
Add all 32 to your calendar (.ics) → With an account.
Among the 316 studies in Crohn Disease with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Enterome small molecule drug EB8018 is a first-in-class FimH blocker to be studied in Crohn's disease patients. The proposed indication for EB8018, as an add-on therapy, will be the treatment of adult patients suffering from Crohn's disease.
This open-label, multicenter study will enroll 8 evaluable patients with active Crohn's disease and will consist of 2 parts. Part 1 will include 2 sentinel patients with a single dosing period followed by a 13-day multiple dosing period. Part 2 will include the 6 remaining patients with multiple dosing only. This Phase 1b study will investigate the PK, safety, preliminary effects of the gut microbiome, and inflammatory biomarkers of EB8018 following 13 days of consecutive BID oral dosing in patients with Crohn's disease.
Part 1 of this study will demonstrate a single oral dose of EB8018 that is safe and tolerable in patients with Crohn's disease and Part 2 of this study will characterize the PK profile when administered as multiple oral doses.
Selection Criteria:
EB8018: 3000 mg for the single dose in Part 1 (2 sentinel patients) and 1500 mg BID for multiple dose administration over 13 days in Parts 1 and 2 (2 sentinel patients and 6 remaining patients), oral.
Drug: EB8018 (First-in-class FimH blocker)
Drug: EB8018 EB8018 is an orally administered, first-in-class, FimH blocker • In Part 1, a single oral dose of EB8018 3000 mg will be administered to the 2 sentinel patients in the morning on Day 1. In the multi-dose treatment period (part 1 and 2), multiple oral doses of EB8018 1500 mg will be administered to 2 + 6 patients BID (in the morning and evening) on Days 1 through 13.
Also known as: EB8018
Cmax
Maximum observed plasma concentration
Time frame: Day1, Day13
Tmax
Time to maximum observed plasma concentration
Time frame: Day1
AUC0-24
Area under the plasma concentration time curve from time 0 to 24 hours
Time frame: Day1; Day13
T1/2
Terminal elimination half-life
Time frame: Day1; Day13
AE
Adverse events
Time frame: Up to Day22
RR
Inter-Beat intervalle (sec)
Time frame: Up to Day22
QRS complex
intervalle (sec)
Time frame: Up to Day22
QT
duration (sec)
Time frame: Up to Day22
PR
intervalle (sec)
Time frame: Up to Day22
HR
Heart rate (bpm)
Time frame: Up to Day22
BP
Blood pressure (mmHg)
Time frame: Up to Day22
RR
Respiratory rate (breaths per minute)
Time frame: Up to Day22
Temp
Temperature (C°)
Time frame: Up to Day22
Gut Microbiome
Overall gene richness and relative abundance of Bacteroidetes, Enterobacteriaceae, and Firmicutes from sequencing of stool samples.
Time frame: Up to Day22
Inflammatory Biomarkers
C-reactive protein
Time frame: Up to Day22
Inflammatory Biomarkers
Fecal calprotectin
Time frame: Up to Day22
CDAI score
CDAI calculation will be dependent on the parameters recorded in the subjects' diary and the parameters assessed at clinic visit by the investigator.
Time frame: Up to Day22
Ran from Mar 2018 to primary completion in Nov 2019, 20 months.
Of 33 industry-sponsored phase 1 interventional studies under Crohn Disease, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 28. This study's 20 months is above that.
Counting every sponsor, half of 61 studies reached it within 22 months; a quarter within 10 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Enterome